Downstream Hatch-Waxman: Unforeseen IP Ramifications

Law360, New York (July 19, 2005, 12:00 AM EDT) -- Litigation challenging patents on branded drugs has increased exponentially since the passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the "Hatch Waxman Act").  As a result of the Act, branded drug manufacturers have faced challenges from generic drug companies to their pharmaceutical patents.  This is not surprising.  The drafters of the Hatch Waxman Act intended and fully anticipated that patent litigation would be a direct result of the Act.  The purpose of the Act was to expedite...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.